Cyma Bay Therapeutics, Inc. CBAY
We take great care to ensure that the data presented and summarized in this overview for CymaBay Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CBAY
View all-
Ra Capital Management, L.P. Boston, MA6.94MShares$02.7% of portfolio
-
Janus Henderson Group PLC London, X06.1MShares$00.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.47MShares$00.01% of portfolio
-
Perceptive Advisors LLC New York, NY4.02MShares$02.32% of portfolio
-
Holocene Advisors, LP New York, NY2.99MShares$00.28% of portfolio
-
Octagon Capital Advisors LP New York, NY2.67MShares$010.53% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.57MShares$00.15% of portfolio
-
Fred Alger Management, LLC New York, NY1.97MShares$00.26% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.8MShares$02.56% of portfolio
-
Foresite Capital Management Iii, LLC Larkspur, CA1.64MShares$015.17% of portfolio
Latest Institutional Activity in CBAY
Top Purchases
Top Sells
About CBAY
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Transactions at CBAY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2024
|
Charles Mc Wherter President of R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,938
-100.0%
|
-
|
|
Mar 22
2024
|
Klara Dickinson Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,000
-100.0%
|
-
|
|
Mar 22
2024
|
Harish Shantharam Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,125
-100.0%
|
-
|
|
Mar 22
2024
|
Sujal Shah Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
406,670
-100.0%
|
-
|
|
Mar 22
2024
|
Robert James Wills |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,000
-100.0%
|
-
|
|
Mar 22
2024
|
Paul T Quinlan General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,262
-100.0%
|
-
|
|
Mar 22
2024
|
Kurt Von Emster |
SELL
Sale (or disposition) back to the issuer
|
Direct |
90,000
-100.0%
|
-
|
|
Mar 13
2024
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
41,824
+37.31%
|
$292,768
$7.89 P/Share
|
|
Mar 13
2024
|
Sujal Shah Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
139,119
+4.11%
|
$834,714
$6.1 P/Share
|
|
Feb 12
2024
|
Janet Dorling |
SELL
Open market or private sale
|
Direct |
6,000
-100.0%
|
$186,000
$31.97 P/Share
|
|
Feb 12
2024
|
Janet Dorling |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$24,000
$4.63 P/Share
|
|
Jan 24
2024
|
Charles Mc Wherter President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
31,938
+40.49%
|
-
|
|
Jan 24
2024
|
Klara Dickinson Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+50.0%
|
-
|
|
Jan 24
2024
|
Harish Shantharam Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,125
+50.0%
|
-
|
|
Jan 24
2024
|
Sujal Shah Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,250
+26.46%
|
-
|
|
Jan 24
2024
|
Paul T Quinlan General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
28,438
+50.0%
|
-
|
|
Jan 19
2024
|
Charles Mc Wherter President of R&D |
SELL
Open market or private sale
|
Direct |
18,403
-18.59%
|
$423,269
$23.67 P/Share
|
|
Jan 19
2024
|
Charles Mc Wherter President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
18,403
+15.25%
|
$92,015
$5.26 P/Share
|
|
Jan 16
2024
|
Paul T Quinlan General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$115,000
$23.58 P/Share
|
|
Jan 16
2024
|
Paul T Quinlan General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.94 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 795K shares |
|---|---|
| Grant, award, or other acquisition | 198K shares |
| Sale (or disposition) back to the issuer | 685K shares |
|---|---|
| Open market or private sale | 548K shares |